

# Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults

NCT06943378

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Just-Evotec Biologics
<b>Enrollment</b>	104 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Healthy men or women 18 to 55 years of age
- BMI between 18 and 32 kg/m<sup>2</sup>
- Negative serum pregnancy test
- Use of highly effective birth control method(s) for a minimum of 60 days prior to consent and is willing to continue use for at least 12 months, or abstinence
- In good general health as determined by medical history, exams and tests

### Exclusion (29)

- Acute illness or fever (≥100.4°F) within 7 days prior to dosing
- Any history of receiving treatment, vaccine, or monoclonal antibodies (mAbs) against the Yersinia pestis bacterium
- Receipt of any vaccine within 30 days prior to Screening, planned receipt of any vaccine prior to Day 1, or planned receipt of any vaccines before 45 days post-injection.
- Any medical condition for which IM injections would be contraindicated in the opinion of the investigator (eg, bleeding disorders, anticoagulant therapy, and severe thrombocytopenia)
- History of congenital or acquired immunodeficiency syndrome
- ... and 24 more (see full listing online)

## Locations (1 total)

---

PPD Las Vegas Clinical Research Unit, Las Vegas, Nevada, United States

---

<https://clinicaltrials.gov/study/NCT06943378>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).